---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-060600"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2026-05-22T20:30:28+00:00"
generated_at: "2026-05-22T20:47:03.594220+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne restates Q1 FY2026 results due to revenue recognition error; reaffirms FY2026 guidance

## Summary
- Revenue overstated by ~$0.5M, net loss understated by ~$0.3M for quarter ended March 31, 2026.
- Restatement caused by customer order modification at quarter-end; no prior periods affected.
- Company reaffirms FY2026 product revenue guidance of at least $10.5M.
- Internal control weakness identified; measures to improve controls are being implemented.
- Audit Committee determined non-reliance on previously filed Form 10-Q for March 31, 2026.

## SEC filing metadata
- accession: 0001213900-26-060600
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2026-05-22T20:30:28+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- confidence: high
- sec_items: 4.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390026060600/0001213900-26-060600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390026060600/ea0291925-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-060600
- JSON: https://secwatch.observer/filing/0001213900-26-060600.json
- Plain text: https://secwatch.observer/filing/0001213900-26-060600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.